EchoSeed Model 6733 Iodine-125 brachytherapy source: improved dosimetric characterization using the MCNP5 Monte Carlo code.

This study primarily aimed to obtain the dosimetric characteristics of the Model 6733 (125)I seed (EchoSeed) with improved precision and accuracy using a more up-to-date Monte-Carlo code and data (MCNP5) compared to previously published results, including an uncertainty analysis. Its secondary aim was to compare the results obtained using the MCNP5, MCNP4c2, and PTRAN codes for simulation of this low-energy photon-emitting source. The EchoSeed geometry and chemical compositions together with a published (125)I spectrum were used to perform dosimetric characterization of this source as per the updated AAPM TG-43 protocol. These simulations were performed in liquid water material in order to obtain the clinically applicable dosimetric parameters for this source model. Dose rate constants in liquid water, derived from MCNP4c2 and MCNP5 simulations, were found to be 0.993 cGyh(-1) U(-1) (±1.73%) and 0.965 cGyh(-1) U(-1) (±1.68%), respectively. Overall, the MCNP5 derived radial dose and 2D anisotropy functions results were generally closer to the measured data (within ±4%) than MCNP4c and the published data for PTRAN code (Version 7.43), while the opposite was seen for dose rate constant. The generally improved MCNP5 Monte Carlo simulation may be attributed to a more recent and accurate cross-section library. However, some of the data points in the results obtained from the above-mentioned Monte Carlo codes showed no statistically significant differences. Derived dosimetric characteristics in liquid water are provided for clinical applications of this source model.

[1]  Experimental determination of the TG-43 dosimetric characteristics of EchoSeed model 6733 I25I brachytherapy source. , 2002, Medical physics.

[2]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2003, Medical physics.

[3]  J. Williamson,et al.  Monte Carlo and experimental dosimetry of an 1251 brachytherapy seed. , 2006, Medical physics.

[4]  R. Sloboda,et al.  Dose calculation for permanent prostate implants incorporating spatially anisotropic linearly time-resolving edema. , 2011, Medical physics.

[5]  L A DeWerd,et al.  Experimental and Monte Carlo determination of the TG-43 dosimetric parameters for the model 9011 THINSeed brachytherapy source. , 2010, Medical physics.

[6]  Zuofeng Li,et al.  Monte Carlo and experimental dosimetry of an I125 brachytherapy seed. , 2006, Medical physics.

[7]  M. Rivard.  Monte Carlo calculations of AAPM Task Group Report No. 43 dosimetry parameters for the MED3631-A/M125I source. , 2001, Medical physics.

[8]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[9]  M. Rivard.  Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 125I brachytherapy sources. , 2009, Medical physics.

[10]  R Nath,et al.  Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Ad Hoc Subcommittee of the Radiation Therapy Committee. , 1998, Medical physics.

[11]  Marco Zaider,et al.  Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[12]  A. Meigooni,et al.  Updated Solid Water™ to water conversion factors for I125 and Pd103 brachytherapy sources. , 2006, Medical physics.

[13]  D. Duggan,et al.  Improved radial dose function estimation using current version MCNP Monte-Carlo simulation: Model 6711 and ISC3500 125I brachytherapy sources. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  F Verhaegen,et al.  Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant. , 2009, Medical physics.

[15]  Kirsten Boedeker,et al.  An analysis of MCNP cross-sections and tally methods for low-energy photon emitters. , 2002, Physics in medicine and biology.

[16]  R M Thomson,et al.  Monte Carlo dosimetry for I125 and Pd103 eye plaque brachytherapy. , 2008, Medical physics.

[17]  J. H. Hubbell,et al.  Tables of X-Ray Mass Attenuation Coefficients and Mass Energy-Absorption Coefficients 1 keV to 20 MeV for Elements Z = 1 to 92 and 48 Additional Substances of Dosimetric Interest , 1995 .

[18]  G. Ibbott,et al.  Monte Carlo calculations of AAPM Task Group Report No. 43 dosimetry parameters for the (125)I I-Seed AgX100 source model. , 2012, Brachytherapy.

[19]  D. Rogers,et al.  Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[20]  L. Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[21]  W. Butler,et al.  Supplement to the 2004 update of the AAPM Task Group No. 43 Report. , 2007, Medical physics.

[22]  B. L. Kirk,et al.  Brachytherapy dosimetry parameters calculated for a new 103Pd source. , 2004, Medical physics.

[23]  Frank Verhaegen,et al.  A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants. , 2008, Medical physics.

[24]  L. Dewerd,et al.  Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code. , 2003, Medical physics.

[25]  A. Meigooni,et al.  A Monte Carlo evaluation of the dosimetric characteristics of the EchoSeed Model 6733 (125)I brachytherapy source. , 2002, Brachytherapy.